ARCHIVES

FDA To Once Again Review ESA Label To Reflect Results Of Negative Studies.

This article is from The Cancer Letter archive.

Vol. 33 No. 45 | December 7, 2007

Download PDF Visit The Full Archive

Related Articles

Center Seeks HER-2 Positive Breast Cancer Patients

August 29, 2003

Piperacillin/Tazobactam Valuable Empiric Therapy For Febrile Neutropenia

October 31, 2003

Surgeons Responsible For Improving Their Role, CCIRC Says

July 8, 1977

In Brief: US Pharmacopeia Names Advisory Panel For Hematologic And Oncological Disease

May 31, 1996

Jury Awards $14 Million To Medenica Patient

February 24, 1995

ODAC Advice: Avoid ESAs In Curative Settings, Require Patients To Sign Informed Consent.

March 14, 2008